Consultation on amendments to the Fees in Respect of Drugs and Medical Devices Order

Current status: Closed

This consultation ran from February 13, 2023 to April 26, 2023.

Who was the focus of this consultation

We engaged with:

• biologics sector
• pharmaceutical sector

Goals of the consultation

We sought feedback on proposed amendments to section 6(2)(c) of the Fees in Respect of Drugs and Medical Devices Order (Fees Order) to replace "designated COVID-19 drug" with "public health emergency drug." This amendment would address the gap created by the repeal of the definition "designated COVID-19 drug" and extend the exception respecting fee remittance to all public health emergency drugs.

What we heard

We received 2 comments from industry groups on the same issue that were deemed out of scope for this consultation. We will address these comments in the response to the Agile consultation.

Related information

• Fees in Respect of Drugs and Medical Devices Order
• Guidance on the Food and Drug Regulations for public health emergency drugs: Preparing a submission

Contact us

Cost Recovery Office
Resource Management and Operations Directorate
Health Products and Food Branch
Health Canada
Main Building 150 Tunney's Pasture Driveway
Ottawa, ON K1A 0K9
PL 0301A

Telephone: 613-957-6690
Email: cro-brc@hc-sc.gc.ca